v3.26.1
SEGMENT REPORTING
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING

NOTE 15 – SEGMENT REPORTING

 

Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker (“CODM”) of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. Effective in 2024, the Company began operating in two segments: Biotechnology and Technology.

 

Biotechnology Segment: This segment is non-revenue generating and incurs expenses by developing its biotechnology product pipeline. The Biotechnology Segment had total assets of $13,783,575 and $8,366,785 as of December 31, 2025 and December 31, 2024, respectively.

 

Technology Segment: This segment is revenue generating and incurs expenses by acquiring technology assets to support and enhance operational capabilities through advanced technologies. The Technology Segment had total assets of $2,370,346 and $541,875 as of December 31, 2025 and December 31, 2024, respectively.

 

The Company believes that this structure reflects its current operational and financial management, and that it provides the best structure for the Company to focus on growth opportunities while maintaining financial discipline. The factors used to identify the Biotechnology and Technology operating segments were the difference in future potential revenue streams and customer base for each segment, the reporting structure for operational and performance information within the Company, and management’s decision to organize the Company around the different future potential revenue generating activities of the segments.

 

Segment information relating the Company's two operating segments for the years ended December 31, 2025 and December 31, 2024 are as follows:

                       
    Year Ended December 31, 2025  
    Biotechnology Segment     Technology
Segment		     Consolidated  
Sales   $ –     $ 1,363,045     $ 1,363,045  
Cost of goods sold     –       180,625       180,625  
Total operating expenses     13,540,971       684,947       14,225,918  
Net (loss) gain from operations   $ (13,540,971 )   $ 497,473     $ (13,043,498 )

 

    Year Ended December 31, 2024  
    Biotechnology Segment     Technology
Segment		     Consolidated  
Sales   $ –     $ –     $ –  
Cost of goods sold     –       –       –  
Total operating expenses     10,054,488       –       10,054,488  
Net loss from operations   $ (10,054,488 )   $ –     $ (10,054,488 )